Concepedia

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, Laura Maria Fogliatto, Iara Gonçalves, José Salvador Rodrigues de Oliveira, Valéria Buccheri,

The Lancet Oncology · 2021 · 258 citations · 25 references

DOI

Concepts

References

25

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al. · American Journal of Clinical Oncology · 1982 · 11.6K citations

, , +8

Revised Response Criteria for Malignant Lymphoma

Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text

, , +15

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Anas Younes, Ajay K. Gopal, Scott E. Smith et al. · Journal of Clinical Oncology · 2012 · 1.5K citations · Full text

, , +17

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Anas Younes, Nancy L. Bartlett, John P. Leonard et al. · New England Journal of Medicine · 2010 · 1.4K citations · Full text

, , +17

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale et al. · Journal of Clinical Oncology · 2017 · 985 citations · Full text

, , +17